Financial compensation for such things as lost wages, disability or discomfort is 
not available. However, I have not waived any legal rights by signing this consent form. 
BENEFITS 
I will neither be charged nor compensated for my participation in the Study. During 
the Study, the Investigator will perform numerous medical examinations and assessments. 
The results of these tests will generally be provided to me through my private physician 
upon written request. 
I may receive an experimental treatment that may be beneficial to my immune 
system during an early stage of HIV infection when no standard treatments are available. It 
is possible that my condition may improve during the Study. However, this experimental 
Treatment may improve my immune defense system, but may not improve my condition. 
Even if the Treatment is effective in some patients, it may not be effective in my case. 
The Treatment is an experimental substance, therefore it may not be available to me 
after the end of the Study. However, my participation will contribute to the search for a 
new treatment for HIV-1 infection. 
Information from this study will help investigators learn more about immune 
defense mechanisms against HIV-1 infection. Results of this study may help determine the 
safety and possible therapeutic effect of gene therapy in humans. 
ALTERNATIVE THERAPIES 
No known approved treatments exist for individuals with HIV-1 infection whose 
CD4 counts are over 500. If my CD4 count is below 500, 1 may elect to receive therapy 
with one of the approved anti-retroviral products such as AZT or ddl; however, I must stop 
taking anti-retrovirals 45 days before the treatment begins and for 70 days thereafter. 
Thus, my participation could require my discontinuing anti-retrovirals for as long as four 
months. However, if a change in my condition warrants, anti-retrovirals can be initiated. 
Alternatively, I may choose to be treated with supportive care only. 
Recombinant DNA Research, Volume 17 
